<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307980</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-9001-LTFU-101</org_study_id>
    <nct_id>NCT03307980</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B</brief_title>
  <official_title>FIX-LONG Study: A Factor IX (FIX) Gene Transfer, Multi-center Evaluation of the LONG-term Safety and Efficacy Study of SPK-9001 (rAAV-Spark100-hFIX-Padua) in Individuals With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term safety follow-up for subjects with Hemophilia B and previously treated in the
      SPK-9001-101 protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the long term level of persistence and potential late or delayed adverse events
      associated with SPK-9001, assessment of the durability of the transgene expression, and
      determination of the effects of SPK-9001 on clinical outcomes in individuals who have
      previously received a single administration of SPK-9001
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SPK-9001-related adverse advents</measure>
    <time_frame>up to 5 years</time_frame>
    <description>adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coagulation Clotting Assay for FIX activity levels</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Coagulation Clotting assays to assess FIX activity levels (percent of normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized (factor FIX) infusion rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>AIR (not including those for surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total factor consumption (IU and volume)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>total quantity of factor infused annually (not including those for surgery) as recorded on the infusion log</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>ABR (not including those for surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of bleeding events</measure>
    <time_frame>up to 5 years</time_frame>
    <description>(spontaneous and traumatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haem-A-QoL</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Quality-of-life (QoL) assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Quality-of-life (QoL) assessment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Hemophilia B</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SPK-9001</intervention_name>
    <description>Observational long-term safety follow-up study of subjects previously treated in the SPK-9001-101 protocol</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Hemophilia B and previously treated in the SPK-9001-101 protocol
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand the purpose and risks of the study, as well as provide signed
             and dated informed consent and authorization to use protected health information (PHI)
             in accordance with national and local study participant privacy regulations.

          2. Subjects who have received a single administration of SPK-9001, and completed the
             required assessments in the SPK-9001-101 clinical study.

        Exclusion Criteria:

          1. Subjects who will not consent for up to 5 years of safety follow-up.

          2. Subjects who are unable or unwilling to comply with the study visits and requirements.

          3. Subjects who have planned to participate in another interventional investigational
             gene transfer study.

          4. Subjects with any clinically significant medical condition that the Investigator
             believes would pose as a safety risk or are not capable of the performing endpoints of
             this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Genetic males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Spark Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Director</last_name>
    <phone>1-215-220-9300</phone>
    <email>clinicaltrials@sparktx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Director</last_name>
      <email>clinicaltrials@sparktx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Director</last_name>
      <email>clinicaltrials@sparktx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Director</last_name>
      <email>clinicaltrials@sparktx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

